Tagged with M

UAE Patrick van der Loo oversees Pfizer’s operations across the vast Middle East, Russia and Africa (MERA) region. In a wide-ranging and insightful conversation, van der Loo outlines the company’s approach to driving access to innovation in emerging markets and resource-constrained environments, including engaging in public-private partnerships where possible. He also…

Hong Kong Former chief executive of the Hong Kong Special Administrative Region (HKSAR) Leung Chun-ying (CY Leung) discusses recent science and technology initiatives like the new Hong Kong University of Science and Technology campus in Guangzhou and the Hong Kong-Shenzhen Innovation and Technology Park, which is set to further foster cooperation between…

Belgium Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far in the Belgian market, and what he sees as Celltrion’s role as driving savings and positive change in the country’s…

Belgium Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus on the hospital generics niche, and his hopes for continuing to meet unmet patient need in Belgium in the coming…

Europe Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some of the challenges in bridging the gap between theoretical vision and practical implementation.*     In 2022, the European Union…

USA Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry veteran Peter Sandor, the company’s SVP and IO Primary Focus Lead. Sandor explains the variety of exciting IO approaches in development at Astellas, how…

Belgium Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years, as well as an important R&D hub. Johan Heylen describes the continuing relevance of the country to the company, the…

UAE Saleh Al Hashimi of the Dubai Health Insurance Corporation (DHIC) gives an overview of the evolution of mandatory health insurance in Dubai over the past decade, with the number of residents under universal health coverage expanding from 500,000 to 4.5 million. Al Hashimi also touches on how the Emirate’s move…

UAE MSD GCC’s new memorandum of understanding (MoU) with The Department of Health Abu Dhabi (DoH) aims to advance research into breast and lung cancer. The deal, signed at the BIO International Convention 2023, marks the continuation of a long-term collaboration between the two entities.   Present at the signing were…

Egypt The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in addition to the possibility of exporting to several emerging markets in Africa.   In addition to Roche Egypt General Manager…

UAE With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge biopharmaceutical innovation than ever before. Here, four leading lights in the region’s pharmaceutical industry highlight some of the most important…

USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…